alexa
Reach Us +44-1764910199
Sodium Oxybatefor Narcolepsy with Cataplexyandndash; Cost-Effective Analysis | OMICS International
E-ISSN: 2314-7326
P-ISSN: 2314-7334
Journal of Neuroinfectious Diseases
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Sodium Oxybatefor Narcolepsy with Cataplexy– Cost-Effective Analysis

Visit for more related articles at Journal of Neuroinfectious Diseases

Abstract

Objective: To assess the cost-effectiveness of sodium oxybate plus antidepressants and stimulants compared with the current standard treatment for narcolepsy with cataplexy in the UK. Methods: We developed a Markov model to assess the costs and benefits of sodium oxybate plus antidepressants and stimulants or current standard treatment based on their effects on the quality of life of patients. The main outcome was the incremental cost-effectiveness ratio (ICER) in terms of costs per additional qualityadjusted life year (QALY) gained over 5 years of treatment. One-way, multi-way and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on the findings. Results: The cost-effectiveness of sodium oxybate plus antidepressants and stimulants were very sensitive to the costs of sodium oxybate (price and dose) and differences in utilities between responders and non-responders. With current clinical evidence, it is recognised that measure of improvement in utilities used in the current model may be an underestimation of the reality. Conclusions: Our analysis suggests that, at the current UK list price, sodium oxybate would not represent good value for money for the NHS. This is unfortunate, since it appears that sodium oxybate is likely to benefit some patients in the management of these two conditions which affect about 0.03% of the UK population.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 12126
  • [From(publication date):
    June-2014 - Jun 24, 2019]
  • Breakdown by view type
  • HTML page views : 8367
  • PDF downloads : 3759
Top